Provided by Tiger Trade Technology Pte. Ltd.

Bioxcel Therapeutics Inc.

0.1814
-0.5374-74.76%
Post-market: 0.1719-0.0095-5.24%19:59 EDT
Volume:58.56M
Turnover:12.57M
Market Cap:5.68M
PE:-0.06
High:0.2299
Open:0.2240
Low:0.1569
Close:0.7188
52wk High:4.29
52wk Low:0.1569
Shares:31.31M
Float Shares:26.89M
Volume Ratio:49.36
T/O Rate:217.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1505
EPS(LYR):-5.7255
ROE:-1766.94%
ROA:-102.43%
PB:-0.05
PE(LYR):-0.03

Loading ...

U.S. Stocks on the MOVE-Cytokinetics, Moderna, Ulta Beauty

Reuters
·
Aug 28

BioXcel Therapeutics - Deal with Teva Includes $57.5 Mln Cash, up to $67.5 Mln Development Milestones, $20 Mln Commercial Milestones - SEC Filing

THOMSON REUTERS
·
Aug 28

BioXcel Therapeutics Files for Chapter 11, Agrees to Sell Assets to Teva in 363 Process

Reuters
·
Aug 28

BioXcel Therapeutics - Teva to Serve as Stalking Horse Bidder in 363 Auction Process

THOMSON REUTERS
·
Aug 28

BioXcel Therapeutics - Secures $19 Mln in Dip Financing from Existing Secured Lenders

THOMSON REUTERS
·
Aug 28

BioXcel Therapeutics - Asset Sale Includes Igalmi and Pending Snda for Bxcl501 for At-Home Use

THOMSON REUTERS
·
Aug 28

BioXcel Therapeutics - Igalmi Remains Commercially Available; Supply to Continue During Sale Process

THOMSON REUTERS
·
Aug 28

BioXcel Therapeutics Enters into Asset Sale Agreement with Teva Pharmaceuticals

THOMSON REUTERS
·
Aug 28

BioXcel Falls After Filing for Chapter 11 Bankruptcy

Reuters
·
Aug 28

BioXcel Therapeutics Files for Chapter 11 Bankruptcy in the U.S.- Court Filing

THOMSON REUTERS
·
Aug 28

BioXcel Therapeutics Lists Estimated Liabilities in Range of $100 Mln to $500 Mln and Assets in Range of $10 to $50 Mln - Court Filing

THOMSON REUTERS
·
Aug 28

BioXcel Therapeutics - Lenders Provide $1.25 Mln in Additional Loans Under Amendment No. 14 Term Loans - SEC Filing

THOMSON REUTERS
·
Aug 25

BioXcel Therapeutics - Enters Fourteenth Amendment to Credit Agreement on August 24, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 25

BioXcel Therapeutics Amends Oaktree-Led Credit Agreement, Extends Deadline for Refinancing Deal to Aug. 28

Reuters
·
Aug 24

BioXcel Therapeutics - Required to Enter Definitive Agreements by August 28, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 24

BioXcel Therapeutics - Enters Thirteenth Amendment to Credit Agreement on August 21, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 24

BioXcel Therapeutics Director Susan E. Atkins Files Initial Beneficial Ownership Statement

Reuters
·
Aug 15

BioXcel Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

BioXcel Therapeutics Q2 Net Loss Narrows to USD 27.4 Million; Revenue Rises 51.67% to USD 182,000

Reuters
·
Aug 14

BioXcel Amends Oaktree-Led Credit Agreement, Cuts Minimum Liquidity Covenant to $3 Million

Reuters
·
Aug 11